MiMedx

462 articles about MiMedx

• MIMEDX Outlines Long-Term Value Creation Strategy at Virtual Investor Day

  12/7/2021

  MiMedx Group, Inc., a transformational placental biologics company, will provide new details about near- and long-term growth opportunities for its multimodal placental tissue platform at ’s virtual Investor Day, which begins at 9:00 a.m. ET.

• MIMEDX Announces Speakers for December 7 Investor Day

  11/30/2021

  Company to Host Virtual Event on December 7, 2021 Beginning at 9:00 a.m. ET.

• MIMEDX to Present at the Piper Sandler 33rd Annual Healthcare Conference

  11/22/2021

  MiMedx Group, Inc., an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, announced that Timothy R. Wright, Chief Executive Officer, and Rohit Kashyap, Ph.D., Chief Commercial Officer, will present at the Piper Sandler 33rd Annual Healthcare Conference taking place November 29 to December 2, 2021.

• MIMEDX to Participate at Upcoming Investor Conferences - Nov 02, 2021

  11/2/2021

  MiMedx Group, Inc., an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, announced that Timothy R. Wright, Chief Executive Officer, Peter M. Carlson, Chief Financial Officer, and Rohit Kashyap, Ph.D., Chief Commercial Officer, will be participating in the following virtual investor conferences:.

• MIMEDX Announces Third Quarter 2021 Operating and Financial Results

  11/2/2021

  MiMedx Group, Inc., an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, announced the filing of its third quarter 2021 Form 10-Q for the period ended September 30, 2021.

• MIMEDX to Host Virtual Investor Day on December 7, 2021

  10/14/2021

  MiMedx Group, Inc., an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, announced that it will host a virtual Investor Day on Tuesday, December 7, 2021 beginning at 9:00 a.m. ET.

• 

  Clinical Catch-Up: September 13-17

  9/20/2021

  With a conference the size of ESMO, it’s impossible to cover all the exciting news, but here are many of the highlights. Here’s a look.

• MIMEDX Announces Effectiveness of Shelf Registration Statement

  9/8/2021

  MiMedx Group, Inc. today announced the shelf registration statement on Form S-3 on file with the Securities and Exchange Commission (SEC) has become effective.

• MIMEDX to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

  9/7/2021

  MiMedx Group, Inc. today announced that Timothy R. Wright, Chief Executive Officer, Peter M. Carlson, Chief Financial Officer, and Robert B. Stein, M.D., Ph.D., Executive Vice President, Research and Development, will present at the H.C. Wainwright 23rd Annual Global Investment Conference held on September 13 - 15, 2021.

• MIMEDX Promotes Marion Snyder to Chief of Staff, Senior Vice President, Government Affairs

  8/12/2021

  MiMedx Group, Inc. today announced the promotion of Marion Snyder to Chief of Staff, Senior Vice President, Government Affairs.

• MIMEDX Announces Second Quarter 2021 Operating and Financial Results

  8/3/2021

  MiMedx Group, Inc., an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, announced the filing of its second quarter 2021 Form 10-Q for the period ended June 30, 2021.

• MIMEDX to Host Second Quarter 2021 Operating and Financial Results Conference Call on August 4

  7/20/2021

  MiMedx Group, Inc., an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, announced that it will report operating and financial results for the second quarter ended June 30, 2021 after the market close on Tuesday, August 3, 2021.

• MIMEDX to Present at the Raymond James 2021 Human Health Innovation Conference

  6/16/2021

  MiMedx Group, Inc.today announced that Timothy R. Wright, Chief Executive Officer, Peter M. Carlson, Chief Financial Officer, and Robert B. Stein, M.D., Ph.D., Executive Vice President, Research and Development, will present at the Raymond James 2021 Human Health Innovation Conference on Wednesday, June 23, 2021.

• MIMEDX to Participate at the Jefferies Virtual Healthcare Conference - May 27, 2021

  5/27/2021

  MIMEDX Group, Inc. announced that Timothy R. Wright, Chief Executive Officer, Peter M. Carlson, Chief Financial Officer, and Robert B. Stein, M.D., Ph.D., Executive Vice President, Research and Development, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021 at 2:00 PM Eastern Time.

• MIMEDX Reminds Shareholders to Pre-Register for the Upcoming Virtual 2021 Annual Meeting of Shareholders

  5/25/2021

  MIMEDX Group, Inc., an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, reminded shareholders to pre-register for the upcoming 2021 Annual Meeting of Shareholders, by no later than 10:00 a.m. Eastern on Wednesday, May 26, 2021.

• MIMEDX Reminds Shareholders to Vote at the Upcoming Annual Meeting

  5/12/2021

  Vote FOR MIMEDX’s Experienced and Highly Qualified Directors and Governance Enhancement Proposals

• MIMEDX Files Definitive Proxy Materials and Mails Letter to Shareholders Highlighting Actions Taken to Transform MIMEDX and Drive Significant Value for Shareholders

  5/3/2021

  MIMEDX Group, Inc., an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, announced that it has filed definitive proxy materials with the U.S. Securities and Exchange Commission in connection with its 2021 Annual Meeting of Shareholders, to be held virtually on May 27, 2021 at 10:00 a.m. Eastern Time at www.cesonlineservices.com/mdxg21_vm.

• MiMedx Welcomes Dirk Stevens, Ph.D., as Senior Vice President, Quality Assurance and Regulatory Affairs

  4/28/2021

  Accomplished Regulatory Leader Joins MiMedx Management Team

• MiMedx Announces First Quarter 2021 Financial and Operating Results

  4/28/2021

  MiMedx Group, Inc., an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, announced the filing of its first quarter 2021 Form 10-Q for the period ended March 31, 2021.

• MiMedx to Host First Quarter 2021 Operating and Financial Results Conference Call on April 29

  4/22/2021

  MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that it will report financial results for the first quarter ended March 31, 2021 after the market close on Wednesday, April 28, 2021.